| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2026―Apr―02 |
COVID-19 in Latin America: Clinical and immunological insights, vaccine development, and lessons for pandemic preparedness |
Alejandro Torres-Flores, Eduardo Bautista-Sebastián, Tania Rivera-Hernández, Eduardo Ferat-Osorio, Lourdes Arriaga-Pizano, Arturo Cérbulo-Vázquez, et al. (+4) Dalia Ramírez-Ramírez, Laura Bonifaz, Rosana Pelayo, Constantino López-Macías |
| 2 |
[GO] |
2024―Jun―10 |
Durability of immune responses to SARS-CoV-2 infection and vaccination |
Mehul S. Suthar |
| 3 |
[GO] |
2024―Mar―14 |
Systems biology of B cells in COVID-19 |
Matthew C. Woodruff, Caterina E. Faliti, Ignacio Sanz |
| 4 |
[GO] |
2024―Mar―08 |
Systems analysis of innate and adaptive immunity in Long COVID |
Michael J. Peluso, Mohamed Abdel-Mohsen, Timothy J. Henrich, Nadia R. Roan |
| 5 |
[GO] |
2024―Jan―24 |
Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond |
Evangelos Andreakos |
| 6 |
[GO] |
2023―Aug―29 |
T cell control of SARS-CoV-2: When, which, and where? |
Mariana O. Diniz, Mala K. Maini, Leo Swadling |
| 7 |
[GO] |
2023―Jun―20 |
Immune responses to SARS-CoV-2 infection and vaccination in children |
Petter Brodin |
| 8 |
[GO] |
2023―May―22 |
Systems Analysis of Human Innate Immunity in COVID-19 |
Sophie Müller, Joachim L. Schultze |
| 9 |
[GO] |
2022―Feb―16 |
E-series Resolvin Metabolome, Biosynthesis and Critical Role of Stereochemistry of Specialized Pro-Resolving Mediators (SPMs) in Inflammation-Resolution: Preparing SPMs for Long COVID-19, Human Clinical Trials, and Targeted Precision Nutrition |
Mary Small, Charles N. Serhan, Stephania Libreros, Robert Nshimiyimana |
| 10 |
[GO] |
2021―Nov―27 |
Complexity and Diversity of Immune Responses in COVID-19 |
Michael Mather, Laura Jardine, Ben Talks, Louis Gardner, Muzlifah Haniffa |
| 11 |
[GO] |
2021―Nov―24 |
Introduction to the special issue: Complexity and diversity of immune responses in COVID-19 |
Li Bai, Zhigang Tian |
| 12 |
[GO] |
2021―Nov―20 |
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity |
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, Abtie Abebaw, Melese Getachew, Tengchuan Jin |
| 13 |
[GO] |
2021―Nov―09 |
Myeloid dysregulation and therapeutic intervention in COVID-19 |
Runxia Gu, Tianyang Mao, Qiao Lu, Tina Tianjiao Su, Jun Wang |
| 14 |
[GO] |
2021―Nov―09 |
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities |
Ioanna-Evdokia Galani, Evangelos Andreakos |
| 15 |
[GO] |
2021―Oct―27 |
Hallmarks of immune response in COVID-19: exploring dysregulation and exhaustion |
Alessio Mazzoni, Lorenzo Salvati, Laura Maggi, Francesco Annunziato, Lorenzo Cosmi |
| 16 |
[GO] |
2021―Oct―25 |
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel |
Kevin W. Ng, Nikhil Faulkner, Antoni G. Wrobel, Steve J. Gamblin, George Kassiotis |
| 17 |
[GO] |
2021―Oct―22 |
T cell immunity to SARS-CoV-2 |
Julia Niessl, Takuya Sekine, Marcus Buggert |
| 18 |
[GO] |
2020―Nov―17 |
Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era |
Simone Pecetta, Oretta Finco, Anja Seubert |
| 19 |
[GO] |
2020―Nov―17 |
The immunology of SARS-CoV-2 infections and vaccines |
Lilit Grigoryan, Bali Pulendran |
| 20 |
[GO] |
2020―Apr―03 |
Introduction to the special issue: Tumor antigens in the time of the coronavirus pandemic |
Olivera J. Finn |
